NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
NCT05422105: Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient |
|
|
| Recruiting | N/A | 230 | RoW | 18F-PSMA-1007, [18F]FPSMA-1007 | Primo Biotechnology Co., Ltd, ABX advanced biochemical compounds GmbH | Prostate Cancer, Prostate Neoplasm | 12/24 | 12/24 | | |
